1. Home
  2. TPB vs COAG Comparison

TPB vs COAG Comparison

Compare TPB & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turning Point Brands Inc.

TPB

Turning Point Brands Inc.

HOLD

Current Price

$73.43

Market Cap

1.7B

ML Signal

HOLD

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$42.84

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TPB
COAG
Founded
1988
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Tobacco
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
TPB
COAG
Price
$73.43
$42.84
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$115.00
N/A
AVG Volume (30 Days)
207.8K
286.6K
Earning Date
05-07-2026
N/A
Dividend Yield
0.39%
N/A
EPS Growth
45.33
N/A
EPS
3.11
N/A
Revenue
$463,062,000.00
N/A
Revenue This Year
$13.68
N/A
Revenue Next Year
$11.32
N/A
P/E Ratio
$23.54
N/A
Revenue Growth
28.39
N/A
52 Week Low
$65.80
$27.47
52 Week High
$146.90
$55.42

Technical Indicators

Market Signals
Indicator
TPB
COAG
Relative Strength Index (RSI) 31.84 38.82
Support Level $71.22 $28.51
Resistance Level $91.65 $53.01
Average True Range (ATR) 3.10 3.43
MACD -1.32 -0.83
Stochastic Oscillator 4.62 0.28

Price Performance

Historical Comparison
TPB
COAG

About TPB Turning Point Brands Inc.

Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: